AlzeCure Pharma AB (SE:ALZCUR)
:ALZCUR
ALZCUR Stock Chart & Stats
kr2.44
kr0.16(7.05%)
At close: 4:00 PM EST
kr2.44
kr0.16(7.05%)
Day’s Range― - ―
52-Week Rangekr1.43 - kr4.95
Previous CloseN/A
Volume72.39K
Average Volume (3M)52.87K
Market Cap
kr168.92M
Enterprise Valuekr123.71M
Total Cash (Recent Filing)kr50.34M
Total Debt (Recent Filing)kr5.12M
Price to Earnings (P/E)―
Beta-0.10
Next Earnings
May 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding114,914,450
10 Day Avg. Volume28,042
30 Day Avg. Volume52,872
Financial Highlights & Ratios
PEG Ratio-1.94
Price to Book (P/B)6.11
Price to Sales (P/S)0.00
P/FCF Ratio-5.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.4
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance Sheet FlexibilityModest absolute debt and a low debt-to-equity ratio give the company financial flexibility over the medium term. This reduces near-term default risk, supports continuing R&D investment, and makes it easier to structure licensing or partnership deals without large interest burdens that would strain cash flows.
Partnering/licensing-focused Business ModelAs an R&D-stage biotech, the company’s model of creating assets for out-licensing or partnerships is capital-efficient long term. Successful deals can deliver non-dilutive upfronts and milestone streams, allowing the firm to scale programs without building costly commercial infrastructure.
Strategic Focus On CNS (Alzheimer’s & Pain)Concentrating on CNS indications like Alzheimer’s and pain aligns the pipeline with persistent, high-unmet-need markets that attract partner interest and funding. Structural demand and long development horizons mean successful candidates can generate outsized licensing value and sustained royalty streams.
Bears Say
No Revenue; Persistent Net LossesAbsence of product revenue and widening annual losses indicate the company remains fully pre-commercial and reliant on external funding. Persistent negative profitability erodes retained capital, increases dependency on fundraising, and elevates execution risk if clinical or partnering milestones are delayed.
Negative Operating And Free Cash FlowConsistent negative operating and free cash flow means the firm must repeatedly access capital markets or partners to fund development. This creates dilution risk, constrains the ability to advance multiple programs simultaneously, and can delay reaching value-inflection clinical milestones.
Eroding Equity / Shrinking Capital BufferMaterial decline in shareholders’ equity over several years reduces the company’s capital buffer against setbacks. With returns deeply negative, future financing rounds may be more dilutive or harder to secure, raising the risk that funding constraints slow development or force unfavorable deal terms.
ALZCUR FAQ
What was AlzeCure Pharma AB’s price range in the past 12 months?
AlzeCure Pharma AB lowest stock price was kr1.43 and its highest was kr4.95 in the past 12 months.
What is AlzeCure Pharma AB’s market cap?
AlzeCure Pharma AB’s market cap is kr168.92M.
When is AlzeCure Pharma AB’s upcoming earnings report date?
AlzeCure Pharma AB’s upcoming earnings report date is May 05, 2026 which is in 22 days.
How were AlzeCure Pharma AB’s earnings last quarter?
AlzeCure Pharma AB released its earnings results on Feb 26, 2026. The company reported -kr0.154 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.154.
Is AlzeCure Pharma AB overvalued?
According to Wall Street analysts AlzeCure Pharma AB’s price is currently Overvalued.
Does AlzeCure Pharma AB pay dividends?
AlzeCure Pharma AB does not currently pay dividends.
What is AlzeCure Pharma AB’s EPS estimate?
AlzeCure Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AlzeCure Pharma AB have?
AlzeCure Pharma AB has 114,914,450 shares outstanding.
What happened to AlzeCure Pharma AB’s price movement after its last earnings report?
AlzeCure Pharma AB reported an EPS of -kr0.154 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.188%.
Which hedge fund is a major shareholder of AlzeCure Pharma AB?
Currently, no hedge funds are holding shares in SE:ALZCUR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
AlzeCure Pharma AB
AlzeCure Pharma AB (ALZCUR) is a Swedish pharmaceutical company that focuses on developing innovative therapies for neurodegenerative diseases, with a particular emphasis on Alzheimer's disease and pain management. The company operates in the biotechnology sector, leveraging its expertise in neuroscience to advance its pipeline of drug candidates. AlzeCure's core products include a range of proprietary small molecule drugs that target key pathways involved in neurodegeneration.
Technical Analysis
Orexo AB
―
Klaria Pharma Holding AB
―
Nanexa AB
―
Enzymatica AB
―
Enorama Pharma AB
―